PharVision Advisers’s Medical Properties Trust MPT Stock Holding History

PharVision Advisers’s Portfolio MPT Stock Details MPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-81,365	Closed	-$407K	–	440
2025 Q4	$407K	Buy	81,365 +36,094	+80%	+$188K	0.21%	115
2025 Q3	$230K	Buy	+45,271	New	+$199K	0.13%	395

Other funds holding MPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

WAM

Wilsey Asset Management San Diego, California $681M AUM 6.7% 1-Year Est. Return

PharVision Advisers's MPT Position: Q1 2026 in Review

PharVision Advisers sold out of Medical Properties Trust (MPT) in Q1 2026, closing a stake of 81,365 shares — an estimated $407K sold.

PharVision Advisers first reported a position in MPT in Q3 2025 and held it in 2 quarters. The position peaked at $407K in Q4 2025. 491 funds tracked by Wall St. Rank hold MPT as of Q1 2026.

PharVision Advisers reported no remaining Medical Properties Trust position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 81,365 Medical Properties Trust shares in Q1 2026, an estimated $407K.
PharVision Advisers first reported a position in Medical Properties Trust in Q3 2025 and held it in 2 quarters.
PharVision Advisers's Medical Properties Trust position peaked at $407K in Q4 2025.
491 funds tracked by Wall St. Rank held Medical Properties Trust as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.